MetroLotion is a U.S. brand name for prescription metronidazole lotion 0.75%, formulated for application to the skin in rosacea care. Understanding this exact product matters because metronidazole also appears as vaginal gels, oral tablets and different dermatologic strengths. A brand match requires more than an ingredient name: the route, vehicle, concentration and particular labeled preparation must be correct. The topical metronidazole overview places this product within the broader rosacea formulation family.
MetroLotion is a historical brand identity as well as a recognizable name for a metronidazole lotion. Current generic lotion identity is more actionable than assuming the branded package can still be purchased. The principal pharmacy task is to distinguish the historical or current branded lotion listing from approved generic formulations and from similarly named products. The Galderma MetroLotion branded NDC record shows a marketing end date of August 25, 2025. A product label can remain accessible even after marketing ends for the identified package. A label or FDA record establishes product identity, not a live store offer. If a prescription names MetroLotion, a pharmacist can determine whether that exact product can be obtained or whether the prescriber should consider an appropriately authorized alternative.
This page is a brand-specific reference rather than a second buying hub or an advertisement. It explains the branded lotion's labeling, its vehicle, 0.75% strength and regulatory supply context. For the form-specific guide see the metronidazole lotion product details; for general access questions see the lotion pharmacy access guide. Do not change medication, concentration or application frequency based on a catalogue filter.
MetroLotion contains metronidazole at 0.75% in a lotion vehicle intended for external skin use. Its labeled context is inflammatory papules and pustules of rosacea; it is not an oral antimicrobial prescription or an intravaginal BV product. Because the drug name crosses very different indications and sites of administration, the pharmacy record must explicitly identify the lotion formulation and the skin route. A product whose package does not make those details clear needs clarification.
The brand name MetroLotion tells the reader that the formulation was a 0.75% topical lotion, which differs from creams and gels despite sharing an ingredient. A pharmacist can compare the manufacturer's label, prescribing order and available package identification. A patient should not use a vaginal applicator product on the face or infer that an oral dose is equivalent to a topical amount. The dermatologic product belongs to a distinct treatment plan selected by a healthcare professional.
| Product or listing | Relevant identity | Why it is not interchangeable |
|---|---|---|
| MetroLotion | 0.75% topical lotion | Exact brand-specific label and route must match |
| Topical metronidazole generic | Formulation and 0.75% must be verified | Generic approval applies to particular strengths and forms |
| Other skin metronidazole forms | 0.75% cream or topical gel and 1% gel | Cream, gel and lotion have different vehicles and labeling |
| Metronidazole vaginal gel | Intravaginal product for BV | Wrong route even when a similar percentage appears |
The official DailyMed labeling for MetroLotion supplies the product name, formulation, ingredients, labeled clinical use, precautions and—where recorded—package identifiers. The label should be the starting point for interpreting any advertised branded medicine. An older document may remain accessible even when a specific marketed package has changed or ended. That is not a contradiction: labeling is a regulatory record, while inventory exists at an individual pharmacy and supplier.
The historical Galderma MetroLotion label and NDC are useful for verifying what the brand was. Its recorded marketing end date should be separated from the regulatory and commercial status of generic 0.75% lotion products. To assess the current U.S. regulatory context, combine the exact label with FDA approval or marketing information and ask a pharmacist to verify the present-day product being dispensed. Avoid statements such as 'always available' or 'brand guaranteed' merely because a drug database still recognizes the name.
The lotion base is more than a texture preference. Its formulation contains inactive ingredients that affect the way a product spreads, dries, feels on the skin and is packaged. Those properties may influence individual tolerability, but they do not establish that one formulation is universally more effective than another. A person experiencing stinging, dryness or another concern should discuss the actual product with the prescriber instead of switching vehicles independently.
A lotion may distribute differently across the skin from an emollient cream or a gel. Differences in excipients can matter to a patient with sensitive skin, but lotions should not be represented as universally superior or less irritating without evidence tied to the person and formulation. The treatment plan can also include nonprescription gentle skincare and sun protection as advised for rosacea; neither these measures nor metronidazole itself should be represented as a cure for every form of facial redness. The cream-versus-gel comparison and other formulation guides address these decisions in greater detail.
The label strength is the concentration of metronidazole in the formulation, not a patient-selected dose or a universal equivalence rule. A 0.75% lotion cannot be substituted for a product with another concentration or vehicle merely by applying more or less. The prescription should identify the intended product, application instructions and amount to dispense. Where an order is ambiguous, the pharmacist may need to contact the prescriber rather than guessing.
A 0.75% generic lotion has its own product label and package. The retired branded NDC cannot simply be substituted for another drug code in advertising; a pharmacy should identify the current approved item. In particular, metronidazole vaginal gels can also be labeled with percentages, but they have a different route, applicator system and indication. The vaginal versus topical gel comparison is useful when packaging names could be confused.
FDA-labeled generic 0.75% topical metronidazole lotions are documented, including a 2026 DailyMed generic record; this does not make an older MetroLotion carton current stock. The FDA Orange Book provides information on approved products and therapeutic-equivalence evaluations, but such information must be checked at the actual form and strength level. A pharmacy's generic offer may come from a different labeler or package than the brand. A shared active ingredient by itself is not proof of approved substitution across forms or concentrations.
The Galderma MetroLotion branded NDC record shows a marketing end date of August 25, 2025. A product label can remain accessible even after marketing ends for the identified package. Do not claim the Galderma-branded MetroLotion bottle is actively marketed on the basis of archived drug-label pages. If the prescribed brand cannot be obtained, ask the pharmacist to check whether the order permits an appropriate approved alternative. Any departure from the intended formulation should be reviewed with the prescriber where required. This brand page does not invent a list of distributors, claim available stock or equate all metronidazole products.
DailyMed's archived MetroLotion listing includes a branded Galderma package whose marketing information ends August 25, 2025. That date is a property of the identified package and label record. It should not be stretched into a claim that metronidazole lotion was withdrawn for a safety problem, that no approved lotion exists, or that an old boxed product can still be reliably purchased. The right interpretation is narrower: the named branded package has a recorded marketing end date.
This distinction protects readers from promotional pages that show a historical MetroLotion image next to a generic checkout button. Verify the actual product name, labeler and NDC before treating an offer as brand supply. The pharmacy may be able to fill a prescription with an approved generic lotion under the rules governing the order.
A Fougera metronidazole 0.75% topical lotion label was updated in 2026 and identifies a prescription topical lotion under an abbreviated drug application. It provides stronger evidence for a contemporary generic product category than an archived MetroLotion carton does for the branded package. The generic record still cannot answer whether a certain retail pharmacy has that NDC in stock today.
When comparing availability, separate three questions: did the brand historically exist, is there an approved generic lotion category, and can this specific pharmacy dispense the prescription? The sources answer the first two, while the pharmacy answers the third. Avoid interpreting the existence of a 0.75% cream or gel as evidence for any lotion equivalence.
Topical metronidazole products such as MetroLotion are discussed in care for inflammatory rosacea lesions, including papules and pustules. Rosacea can also involve flushing, persistent redness, sensitive skin or other findings that may respond differently to various treatments. The clinician determines the diagnosis and whether this lotion is suitable, rather than treating any facial redness as an indication for an antibiotic.
The MetroLotion label documents its 0.75% lotion vehicle and the twice-daily use described for that historical branded formulation. It targets rosacea papules and pustules, not persistent erythema as a standalone indication. Lotion texture or a perceived cosmetic benefit is not evidence that this vehicle outperforms gel or cream; if the skin response is unsatisfactory, the clinician should reassess the diagnosis and available formulation rather than rely on an archived brand listing.
An old MetroLotion carton or NDC appearing in a search result is useful for identifying the original 0.75% lotion, but it is not a purchasing offer. The Galderma brand listing has a recorded end date, so the pharmacist should identify an actually dispensable metronidazole lotion and check any required substitution authorization against the prescription. An online seller must still be a legitimate prescription-dispensing U.S. pharmacy; an archived product photo cannot establish either a licensed seller or current inventory.
Because a branded package has a recorded marketing end date, ask about the exact currently dispensed generic 0.75% lotion rather than insisting an old brand bottle is available. Wholesaler inventory is not established by an archived label. For details of broader prescribing mechanics, see topical metronidazole prescription access. If a brand cannot be ordered, a pharmacist may propose an appropriately approved option rather than declaring that any metronidazole cream, lotion or gel is equivalent.
MetroLotion is intended for skin use in the prescribed areas. The product's own label addresses issues such as hypersensitivity, local irritation and avoiding eye contact. Topical systemic exposure is not identical to oral administration, but this is not a reason to ignore the prescribing information or other medicine use. People with reactions or changing symptoms should contact their clinician rather than repeatedly experimenting with different formulations.
The branded MetroLotion directions describe use on affected facial skin after cleansing and advise avoiding the eye area; the archived label also addresses waiting for the lotion to dry before applying cosmetics. Report worsening burning, dryness or other irritation to the treating clinician. A patient obtaining a newer generic lotion should follow the directions provided with that exact dispensed product rather than assuming every historical MetroLotion instruction applies word for word.
Historic MetroLotion brand cost listings are especially vulnerable to being stale. Compare current prescription quotes for an actually dispensable 0.75% lotion, not archived branded packaging. A quote for a different concentration, package size or rosacea vehicle is not a valid like-for-like price comparison. Insurance formularies, deductibles, preferred pharmacies and branded versus generic dispensing may affect out-of-pocket costs even when the prescribed active ingredient has not changed.
Use the topical metronidazole cost overview to distinguish quotations for a current generic 0.75% lotion from archived MetroLotion brand references. Ask what product and package the pharmacy can actually supply and whether the benefit treats that exact lotion as covered. A low price attached to a historical package number is not a reliable claim of availability or a reason to substitute another vehicle.
Before paying or beginning treatment, verify that the label identifies a topical skin lotion, metronidazole 0.75%, the correct brand or pharmacist-approved generic, prescribed directions and package. Check whether the drug is actually intended for rosacea rather than BV or another infection, and read any storage or handling instructions supplied with the medicine.
If any item is inconsistent—especially an unfamiliar route, alternate concentration or discontinued branded package—ask the dispensing pharmacist for clarification and prescriber coordination. If the seller advertises an old MetroLotion carton as in stock, require a clear, legitimate product-identity explanation before proceeding. The aim is a correct and verified medicine, not the fastest possible checkout.
MetroLotion is a branded prescription metronidazole lotion 0.75% for external skin use in rosacea care.
No. MetroLotion is a dermatologic skin product; bacterial vaginosis vaginal products have different formulations and routes.
No. The U.S. MetroLotion product is prescription-only.
Yes. Current labeling exists for generic 0.75% metronidazole lotion; verify the exact approved supplier and prescription match.
Not without appropriate pharmacist review and any required prescriber authorization. Exact route, concentration and formulation must be considered.
The product is for topical skin use; label precautions require avoiding the eyes. Follow the prescriber’s directions for appropriate application sites.
No. Oral Flagyl and dermatologic MetroLotion have different routes, exposure patterns and clinical purposes.
The cited brand NDC has a recorded marketing end date in 2025; current generic lotion supply is a separate question. A product label or historical brand record is not real-time inventory.
Product identity, branded versus generic dispensing, package quantity, insurance terms and pharmacy selection may affect cost.
Confirm topical route, 0.75% concentration, lotion dosage form, prescription directions, active ingredient and licensed pharmacy dispensing.